Condition: Advanced Malignant Tumors · Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and antitumor activity of SSGJ-612 in patients with advanced malignant solid tumors expressing HER2.
This description comes directly from the study's public registry record.
Jun Yao, M.D. · 13663790098 · yaojun74@163.com
Cai'e Wang, M.D. · 13837915297 · 2454544618@qq.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Henan University of Science & Technology | Luoyang, Henan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07032298